Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJH8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,484.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector injections. The delivery order, issued on December 23, 2025, with an ultimate completion date of January 15, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes the issuance of firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial recent contracting activity demonstrating consistent performance across multiple therapeutic categories. The company's comprehensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with delivery orders ranging from under $100 to exceeding $115,000. The parent indefinite delivery contract, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three optional 30-month extension periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the Department of Defense's global military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FDJH8?
SPE2DR26FDJH8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FDJH8 worth?
The government has obligated $10,485 on SPE2DR26FDJH8.
Is contract SPE2DR26FDJH8 an order under another contract?
Yes. SPE2DR26FDJH8 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJH8 competed?
The extent of competition for SPE2DR26FDJH8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award